Related Experiment Video
Updated: Jul 15, 2026
07:00
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
ETB receptor polymorphism is associated with airway obstruction
Camille Taillé1, Armelle Guénégou, Abdelhamid Almolki
1Service de Pneumologie, Hôpital Bichat-Claude Bernard, Assistance Publique-Hôpitaux de Paris, Paris, France. camille.taille@bch.aphp.fr
BMC Pulmonary Medicine
|May 2, 2007
Summary
Genetic variations in the endothelin-1 system influence asthma severity. The EDNRB-30G>A polymorphism is linked to reduced lung function (FEV1) in asthma patients and smokers.
Area of Science:
- Pulmonary Medicine
- Genetics
- Respiratory Research
Background:
- Endothelin-1 (EDN1) plays a role in asthma development, including airway obstruction and inflammation.
- Genetic variations in preproET1, EDNRA, and EDNRB genes, encoding ET-1 precursors and receptors, are potential determinants of asthma severity.
Purpose of the Study:
- To investigate the association between genetic polymorphisms in preproET-1, EDNRA, and EDNRB genes and the degree of airway obstruction in asthma.
Main Methods:
- Polymorphisms in preproET-1, EDNRA, and EDNRB were analyzed in adult asthmatic patients.
- Findings were validated in a large general adult population from the ECRHS II study.
Main Results:
- The EDNRB-30G>A (Leu277Leu) GG genotype was significantly associated with lower FEV1 in asthmatic patients.
- This association was also observed in the general population, particularly in subgroups of asthmatic subjects and smokers.
- No significant associations were found for EDNRA-1363C>T or preproET-1-595G>T polymorphisms with pulmonary function.
Conclusions:
- The EDNRB-30G>A polymorphism may be a key factor in determining airway obstruction.
- Predisposing factors like asthma and tobacco smoke exposure can modify the impact of this genetic polymorphism on airway obstruction.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:26Adrenergic Receptors: β Subtype
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:28Antihypertensive Drugs: Types of β-Blockers
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
01:24Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...